Title:
Building on success: A multi-institutional approach for the production of GMP AAV Vectors
Agreement Value:
$2,526,168.00
Agreement Date:
Mar 17, 2020 - Mar 31, 2023
Description:
The Recipient is proposing to take advantage of previous government investments in GMP manufacturing facilities in Alberta and Ontario to create a cohesive, collaborative team approach for the production of life-saving virus-based therapeutics. The Recipient's internationally recognized track record of producing GMP grade virus products is unrivalled in Canada. The Recipient has in place, a team of highly skilled and qualified personnel who have made virus-based products for the last decade that have and continue to be used in human clinical trials around the world. The Recipient's plan is to sue this team and upgraded facilities to rapidly create a pipeline that generates novel vectors for the treatment of rare diseases such as Lipoprotein Lipase Deficiency a disease which particularly impacts French Canadian Families. Working closely with Scientist from the National Research Council, the Recipient will optimize manufacturing processes to efficiently and economically create novel medicines that are affordable to the Canadian Healthcare System and accessible to all Canadians in need.
Organization:
National Research Council Canada
Expected Results:
In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems.
Location:
Ottawa, Ontario, CA K1H 8L6
Reference Number:
172-2021-2022-Q4-947629
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
886822212
Recipient Type:
Not-for-profit organization or charity
Additional Information:
This agreement has been amended 1 time(s). The total amended value is 2,526,200 dollars and the end date of this agreements has been modified by 455 days
Amendment Date
Mar 27, 2022
Recipient's Legal Name:
Ottawa Hospital Research Institute
Federal Riding Name:
Ottawa South
Federal Riding Number:
35077
Program:
Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives
Program Purpose:
Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas.